Enzymatica AB (STU:EN9) Total Receivables: €0.91 Mil (As of Mar. 2026)


STU:EN9 Enzymatica AB STU:EN9
57 GF Score
Price €0.20
GF Value €0.16
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB Total Receivables?

Enzymatica AB STU:EN9 +0.51% 57 Total Receivables is €0.91 Mil as of Mar. 2026. GuruFocus rates STU:EN9 with a GF Score™ of 57/100 and a GF Value™ of €0.16. The stock has 2 warning signs investors should review.

Enzymatica AB's Total Receivables for the quarter that ended in Mar. 2026 was €0.91 Mil.

Enzymatica AB Total Receivables Related Terms

Enzymatica AB Total Receivables Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB Total Receivables Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 1.61 1.12 1.18 0.98

Enzymatica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.10 1.74 0.98 0.91
STU:EN9
57GF Score
Enzymatica AB STU:EN9
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.91 Mil mean?
Enzymatica AB (STU:EN9) has a Total Receivables of €0.91 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Enzymatica AB and its competitors.
Is Enzymatica AB's Total Receivables too high?
Enzymatica AB's current Total Receivables is €0.91 Mil. Overall, Enzymatica AB has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Total Receivables compare to ZTS and UTHR?
Enzymatica AB's Total Receivables of €0.91 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Enzymatica AB and its competitors. Enzymatica AB's current Total Receivables is €0.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Enzymatica AB (STU:EN9) has a current Total Receivables of €0.91 Mil. The stock's GF Value™ is €0.16, compared to a current price of €0.20 — trading 22.5% above its estimated fair value. The current Total Receivables is €0.91 Mil. Enzymatica AB's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Enzymatica AB (STU:EN9), the current Total Receivables is €0.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (STU:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.20 is trading 22.5% above its estimated GF Value™ of €0.16.

Key valuation signals for STU:EN9:

  • Total Receivables: €0.91 Mil
  • GF Value™: €0.16 vs. price of €0.20 (22.5% above fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the STU:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:SwedenEN9:Germany
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
57GF Score

Get the complete analysis for STU:EN9

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.16
GF Value